Genetic loss of function analysis is a powerful approach for the study of protein function. However, some cell biological questions are difficult to address using traditional genetic strategies often due to the lack of appropriate genetic model systems. Here, we present a general strategy for the design and syntheses of 
Introduction
The selective loss of critical cellular proteins and subsequent analysis of the resulting phenotypes have proven to be extremely useful in genetic studies of in vivo protein function. In recent years, genetically modified knockout cell lines and animals have allowed biological research to advance with unprecedented speed. Chemical genetic approaches, using small molecules to induce changes in cell phenotype, are complimentary to traditional genetics. Many chemical genetic strategies use knowledge gained from natural product mode of action studies 1, 2, 3 , while others employ chemical inducers of dimerization to manipulate intracellular processes 4, 5, 6, 7 . To date, however, there have been few attempts to design small molecules which induce the destruction (rather than inhibition) of a targeted protein in an otherwise healthy cell. Access to such reagents would provide a chemical genetic alternative to the traditional ways of interfering with protein function, resulting in "chemical knockouts." Importantly, a small molecule capable of inducing this process could do so without any genetic manipulation of the organism, thus allowing one to target proteins that are not readily accessible by traditional genetic means (i.e., genes essential for proliferation and early development).
In principle, targeted proteolytic degradation could be an effective way to accomplish the removal of a desired protein. Given the central role of the ubiquitin-proteasome pathway in protein degradation within the cell 8 , reagents capable of redirecting the substrate specificity of this pathway would be useful as experimental tools for modulating cellular phenotype and potentially act as drugs for inducing the elimination of disease-promoting proteins. We present here a general strategy for designing molecules capable of inducing the proteolysis of a targeted protein via the ubiquitin-proteasome pathway, as well as the first evidence that such molecules are effective upon addition to living cells.
Protein degradation, like protein synthesis, is an essential part of normal cellular homeostasis. As the major protein degradation pathway, the ATP-dependent ubiquitin-proteasome pathway has been implicated in the regulation of cellular processes as diverse as cell cycle progression 9 , antigen presentation 10 , the inflammatory response 11 , transcription 12 , and signal transduction 13 . The pathway involves two discrete steps: (i) the specific tagging of the protein to be degraded with a polyubiquitin chain and (ii) the subsequent degradation of the tagged substrate by the 26S proteasome, a multicatalytic protease complex. Ubiquitin, a highly conserved 76 amino acid protein 14 , is conjugated to the target protein by a three part process. First, the C-terminal carboxyl group of ubiquitin is activated by a ubiquitin-activating enzyme (E1). The thioester formed by attachment of ubiquitin to the E1 enzyme is then transferred via a transacylation reaction to an ubiquitin-conjugating enzyme (E2). Finally, ubiquitin is transferred to a lysine (or, less commonly, the amino terminus) of the protein substrate that is specifically bound by an ubiquitin ligase (E3) 15 . Successive conjugation of ubiquitin to internal lysines of previously added ubiquitin molecules leads to the formation of polyubiquitin chains 16 . 20 . Encouraged by our success with PROTACS-1, -2, and -3, we next directed our efforts toward the design of molecules capable of accomplishing the inducing proteolysis simply upon addition to cells.
Results

Development of a Cell Permeable PROTAC: PROTAC-4
For the design of PROTAC-4, we used a protein target/ligand pair developed by ARIAD Pharmaceuticals. The F36V mutation of FK506 Binding Protein (FKBP12) generates a 'hole' into which the artificial ligand AP21998 (1) fits via a hydrophobic "bump," thus conferring specificity of this particular ligand to the mutant FKBP over the wild type protein 21, 22 . Inclusion of AP21998 as one domain of PROTAC-4 thus allows it to target (F36V)FKBP12 proteins orthogonally, without disrupting endogenous FKBP12 function. Given the lack of small molecule E3 ubiquitin ligase ligands, we chose the seven amino acid sequence ALAPYIP for the E3 recognition domain. This sequence has been shown to be the minimum recognition domain for the von Hippel-Lindau tumor suppressor protein (VHL) 23 , part of the VBC-Cul2 E3 ubiquitin ligase complex. Under normoxic conditions, a proline hydroxylase catalyzes the hydroxylation of hypoxia inducible factor 1a (HIF1a) at P564 24 (the central proline in our sequence), resulting in recognition and polyubiquitination by VHL. HIF1a is thus constitutively ubiquitinated and degraded under normoxic conditions 25, 26 . Finally, we included a poly-D-arginine tag on the carboxy terminus of our peptide sequence to confer cell permeability and resist nonspecific proteolysis.
Polyarginine sequences fused to proteins have been shown to facilitate translocation into cells 27, 28 via a mechanism that mimics that of the Antennapedia 29 and HIV Tat proteins 30 . Because a molecule fused to the polyarginine sequence should in principle be cell permeable, the necessity of PROTAC microinjection is circumvented. This design element also allows greater flexibility in the types of ligands that could be used in future PROTACs, since polarity of the compound is no longer an issue for membrane permeability. We hypothesized that the PROTAC-4 would enter the cell, be recognized and hydroxylated by a prolyl hydroxylase, and subsequently bound by both VHL E3 ligase and the mutant FKBP12 target protein. PROTAC-mediated recruitment of FKBP12 to the VBC-Cul2 E3 ligase complex would be predicted to induce FKBP12 ubiquitination and degradation as in Figure 1 .
5
The F36V FKBP12 ligand AP21998 (1) was synthesized as previously described, 21,22 as a 1:1 mixture of diastereomers at C9. Treatment of 1 with the benzyl ester of aminocaproic acid followed by removal of the benzyl group afforded 2 in 85% crude yield after 2 steps. It is important to note that although this material was carried through as a mixture of two diastereomers at C9, each diastereomer has previously been shown to bind to the target 2 2 . Standard peptide coupling conditions were used to label the peptide sequence. HPLC purification yielded 3 (PROTAC-4) with 17% recovery from 1 (Scheme 1).
In order to monitor the abundance of the targeted protein, we generated a vector capable of activity.
Implementation of a DHT-Based PROTAC: PROTAC-5
To test the robustness of this approach for the induction of intracellular protein degradation, we next targeted a protein which, although still modified, is closer to being clinically relevant. It has been
shown that the androgen receptor (AR) can promote the growth of prostate tumor cells, even in some androgen independent cell lines 32 . We hypothesized that a PROTAC could be utilized to degrade AR, potentially yielding a novel strategy to repress tumor growth. With this in mind, we designed PROTAC-5, 
Discussion
These experiments highlight the general applicability of our strategy to target and degrade proteins in vivo. Moreover, the modularity of the PROTAC design offers the possibility to synthesize similar PROTAC molecules targeting different intracellular targets. We have shown that the ligand for the target protein can be varied using both natural and synthetic ligands. Although the linker length has not been fully explored, we have demonstrated that a spacer consisting of two aminocaproic acids (12 atoms) is flexible enough to accommodate some structural variation in the target and E3 ligase proteins yet bring the proteins within close proximity. Since ubiquitination occurs most commonly on an exposed lysine, different spacer lengths may be required to accommodate the structures of different target proteins.
7
Small molecules have previously been implicated in inducing ubiquitination and degradation of proteins, most notably geldanamycin derivatives act by controlling target interaction with molecular chaperones 35, 36, 37, 38 . However, there are often specificity issues with these approaches, and the exact mechanism of induced degradation is not clear. In addition, no unified strategy has been presented to confront these issues. Our strategy represents the first attempt to develop a general method for small molecule-induced targeted proteolysis via the ubiquitin-proteasome pathway in intact cells.
PROTACS could in principle be used to target almost any protein within a cell and selectively initiate its degradation, resulting in a "chemical knockout" of protein function. A notable advantage to our strategy is that proteolysis is not dependent on the active site inhibition of the target-any unique site of a protein may be targeted, provided that there are exposed lysines within proximity for the attachment of ubiquitin. Because some E3 ligases are expressed in a tissue specific manner, this also raises the possibility that PROTACS could be used as tissue specific drugs.
Several applications for this technology can be envisioned. First, PROTACS could be used to control a desired cellular phenotype, for example via the induced degradation of a crucial regulatory transcription factor which is difficult to target pharmaceutically. "Chemical knockout" of a protein could prove viable as an alternative for a genetic knockout, which would be extremely valuable in the study of protein function. This strategy could also provide significantly more temporal control than gene inactivation at the DNA or RNA level. Second, diversified libraries of PROTACS could be used to screen for phenotypic effects in a chemical genetic fashion. This strategy could be used either to identify novel ligands for a target by monitoring degradation of the target or to identify new therapeutically vulnerable protein targets by studying phenotypic change as a result of selective protein degradation ( Figure 5 ). This chemical genetic strategy would employ a library of PROTAC molecules with identical E3 ubiquitin ligase domains but chemically diverse target ligands. After PROTAC library incubation with cultured cells and detection of the desired cellular phenotype (e.g., inhibition of pro-inflammatory signaling), one could identify the protein that was degraded by incubation with the PROTAC. A number of approaches could be used to identify the PROTAC-targeted protein, including affinity chromatography and differential proteomic technologies such as ICAT 39 . In a modification of this strategy, a library of PROTACS could be screened to identify a ligand for a particular target by monitoring degradation of the target protein (e.g., loss of GFP fusion protein). Finally, PROTACS could be used as drugs to remove toxic or diseasecausing proteins. This strategy is particularly appealing since many diseases, including several cancers, are 8 dependent on the presence or overexpression of a small number of proteins. The large number of potential uses for this technology coupled with the success of these experiments suggests that PROTACS could find broad use in the fields of cell biology, biochemistry, and potentially medicine. supplemented with 10% fetal bovine serum, 100 units/mL penicillin, 100 mg/mL streptomycin and 2 mM L-glutamine. All cell lines were maintained at temperature of 37°C in a humidified atmosphere of 5% CO 2 .
Experimental
To generate cells stably expressing a particular fluorescent target protein, the parent cell line was grown to 70% confluency and transfected using calcium phosphate precipitation of the designated cDNA.
Following transfection, cells were split 1:10 into culture medium supplemented with 600 g/mL G418
(GIBCO-Invitrogen). Individual clones which optimally expressed fluorescent target protein were identified and expanded under selection for further experimentation. 
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Preparation and characterization information for compounds 3 and 5 and the HIF-polyarginine peptide. 
